PMID- 23394540
OWN - NLM
STAT- MEDLINE
DCOM- 20131030
LR  - 20191027
IS  - 1996-3181 (Electronic)
IS  - 1871-5273 (Linking)
VI  - 12
IP  - 2
DP  - 2013 Mar
TI  - Albumin induces neuroprotection against ischemic stroke by altering Toll-like 
      receptor 4 and regulatory T cells in mice.
PG  - 220-7
AB  - The objective of this study was to characterize the effect of albumin therapy on 
      the expression of Toll-like receptor 4 (TLR 4), anti-inflammation cytokines and 
      CD4(+)CD25(+)forkhead box P3 (Foxp3)(+) regulatory T lymphocytes (Treg cells) in 
      the ischemic brain and peripheral immune system after Middle Cerebral Artery 
      Occlusion (MCAO). Adult male Kunming mice were subjected to MCAO, the suture was 
      withdrawn 2 h later followed by an intravenous administration of 25% albumin 
      (1.25 g/kg) or saline (5 ml/kg) through caudal vein. We demonstrated that albumin 
      administration elevated the serum albumin level supranormally at 6 h and 24 h 
      after MCAO in mice. In addition, we showed that both in the ischemic brain and in 
      the spleen, albumin administration significantly depressed the increase of TLR 4 
      mRNA expression by quantitative real-time polymerase chain reaction (QRT-PCR), 
      and significantly increase the anti-inflammatory related interleukin-10 (IL-10) 
      and transforming growth factor beta1 (TGF-beta1) mRNA expression by 
      transcription-polymerase chain reaction (RT-PCR) after MCAO. In the spleen, 
      compared to sham group, strong TLR 4 immunoreactivity was noted in the saline 
      group; while compared to saline group, albumin administration markedly reduced 
      the immunoreactivity of TLR 4 after MCAO by immunohistochemistry. Moreover, 
      albumin administration significantly increased the percentage of Treg in spleen 
      CD4(+) cells by flow cytometry. In conclusion, the decrease of TLR 4 expression 
      and the increase of Treg cell, IL-10, and TGF-beta1 expression may partly contribute 
      to the neuroprotective effect of albumin therapy on MCAO induced immune 
      inflammatory responses.
FAU - Wang, Min
AU  - Wang M
AD  - Department of Pathophysiology, School of Basic Medical Sciences, Tianjin Medical 
      University, Tianjin 300070, China.
FAU - Wang, Yongming
AU  - Wang Y
FAU - He, Jing
AU  - He J
FAU - Wei, Siyu
AU  - Wei S
FAU - Zhang, Na
AU  - Zhang N
FAU - Liu, Fengyong
AU  - Liu F
FAU - Liu, Xin
AU  - Liu X
FAU - Kang, Yi
AU  - Kang Y
FAU - Yao, Xiaomei
AU  - Yao X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - CNS Neurol Disord Drug Targets
JT  - CNS & neurological disorders drug targets
JID - 101269155
RN  - 0 (Albumins)
RN  - 0 (Antigens, CD)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (RNA, Messenger)
RN  - 0 (Serum Albumin)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Albumins/*therapeutic use
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Brain/drug effects/metabolism
MH  - Disease Models, Animal
MH  - Flow Cytometry
MH  - Gene Expression Regulation/drug effects
MH  - Infarction, Middle Cerebral Artery/blood/*drug therapy/pathology
MH  - Interleukin-10/genetics/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Neuroprotective Agents/*therapeutic use
MH  - RNA, Messenger/metabolism
MH  - Serum Albumin/metabolism
MH  - Spleen/drug effects/metabolism
MH  - Statistics, Nonparametric
MH  - T-Lymphocytes, Regulatory/*drug effects
MH  - Time Factors
MH  - Toll-Like Receptor 4/genetics/*metabolism
MH  - Transforming Growth Factor beta1/genetics/metabolism
EDAT- 2013/02/12 06:00
MHDA- 2013/10/31 06:00
CRDT- 2013/02/12 06:00
PHST- 2012/05/31 00:00 [received]
PHST- 2012/07/12 00:00 [revised]
PHST- 2012/07/23 00:00 [accepted]
PHST- 2013/02/12 06:00 [entrez]
PHST- 2013/02/12 06:00 [pubmed]
PHST- 2013/10/31 06:00 [medline]
AID - CDTCNSND-EPUB-20130204-22 [pii]
AID - 10.2174/18715273113129990058 [doi]
PST - ppublish
SO  - CNS Neurol Disord Drug Targets. 2013 Mar;12(2):220-7. doi: 
      10.2174/18715273113129990058.